Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol and Probucol Combination in Diabetic Nephropathy
NCT01252056Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Mar 2010
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cilostazol in diabetic nephropathy (DN) (3 arms), sponsored by Otsuka Holdings. Primary endpoint: Nephropathy development at 96 weeks. Started Mar 2010; status: completed.
02
Drugs
cilostazol
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01252056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01252056.